abstract |
A use of a pharmaceutical composition is provided for treating peripheral atherosclerotic disease (arteriosclerosis obliterans) and/or intermittent claudication containing an HMG CoA reductase inhibitor alone and/or inhibitor of the enzyme squalene synthetase and optionally a pharmaceutical which reduces serum cholesterol by a mechanism other than inhibiting production of the enzyme HMG CoA reductase or the enzyme squalene synthetase, for example, probucol or gemfibrozil. |